Patent ID: 11892450
Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Field: Measurement (Instruments)
Classification: CPC G  A  C | IPC C  G

Claim 19:
20. A method for treating a subject having a plasma kallikrein (pKal)-mediated disorder, the method comprising administering to the subject an effective amount of a therapeutic agent,
wherein the subject has a reduced level of plasma protease C1 inhibitor (C1-INH) that is capable of binding to a capture reagent as compared to a reference value, and
wherein the capture reagent comprises:
i) an active form of Factor XII, or a C1-INH-binding fragment thereof;
ii) an active form of pKal, or a C1-INH-binding fragment thereof, or
iii) a combination of i) and ii);

wherein the therapeutic agent is a plasma kallikrein inhibitor, a bradykinin B2 receptor antagonist or a C1-INH replacement agent; and
wherein the pKal-mediated disorder is selected from the group consisting of rheumatoid arthritis, Crohn's disease, brain ischemia/reperfusion injury, cerebral edema, macular edema, arterial or venous thrombosis, thrombosis associated with ventricular assist devices or stents, heparin-induced thrombocytopenia with thrombosis, thromboembolic disease, intestinal bowel disease, and hereditary angioedema (HAE).